Cyril H Benes

List of Publications by Year
in descending order

102	16,917	34016	40881
papers	citations	52 h-index	93 g-index

109	109	109	25982
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Effective drug combinations in breast, colon and pancreatic cancer cells. Nature, 2022, 603, 166-173.	13.7	154
2	EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusionâ€“Positive Cholangiocarcinoma. Cancer Discovery, 2022, 12, 1378-1395.	7.7	33
3	Catastrophic ATP loss underlies a metabolic combination therapy tailored for MYCN -amplified neuroblastoma. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	10
4	Alginate-based 3D cancer cell culture for therapeutic response modeling. STAR Protocols, 2021, 2, 100391.	0.5	2
5	Venetoclax-based Rational Combinations are Effective in Models of MYCN-amplified Neuroblastoma. Molecular Cancer Therapeutics, 2021, 20, 1400-1411.	1.9	10
6	Abstract 1053: A large cellular screen charting the landscape of synergistic drug combinations in lung cancer. , 2021, , .		0
7	Pharmaceutical Interference of the EWS-FLI1â€“driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma. Molecular Cancer Therapeutics, 2021, 20, 1868-1879.	1.9	8
8	Screening and Validation of Molecular Targeted Radiosensitizers. International Journal of Radiation Oncology Biology Physics, 2021, 111, e63-e74.	0.4	10
9	Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms. Cancer Cell, 2021, 39, 1531-1547.e10.	7.7	106
10	PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3KÎ± Inhibitors in Breast Cancer. Cancer Discovery, 2020, 10, 72-85.	7.7	154
11	Radioresistance of KRAS/TP53â€mutated lung cancer can be overcome by radiation dose escalation or EGFR tyrosine kinase inhibition in vivo. International Journal of Cancer, 2020, 147, 472-477.	2.3	36
12	Pharmacological Targeting of Vacuolar H+-ATPase via Subunit V1G Combats Multidrug-Resistant Cancer. Cell Chemical Biology, 2020, 27, 1359-1370.e8.	2.5	13
13	MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer. Clinical Cancer Research, 2020, 26, 2535-2545.	3.2	127
14	EXTH-74. IND-ENABLING CHARACTERIZATION OF DUAL DRD2- AND ClpP-TARGETING AGENT ONC206 AS THE NEXT IMIPRIDONE FOR CLINICAL NEURO-ONCOLOGY. Neuro-Oncology, 2020, 22, ii103-ii103.	0.6	2
15	BIOM-60. BIOMARKER EVALUATION FOR IMIPRIDONE ONC206 REVEALS ClpP, ATF4, MYC, EGFR and HIF1 AS KEY PREDICTORS OF ANTI-CANCER EFFICACY. Neuro-Oncology, 2020, 22, ii14-ii15.	0.6	0
16	Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer. Oncogene, 2019, 38, 6399-6413.	2.6	160
17	Passenger hotspot mutations in cancer driven by APOBEC3A and mesoscale genomic features. Science, 2019, 364, .	6.0	229
18	Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia. Leukemia, 2019, 33, 2805-2816.	3.3	47

#	Article	IF	Citations
19	Stromal Microenvironment Shapes the Intratumoral Architecture of Pancreatic Cancer. Cell, 2019, 178, 160-175.e27.	13.5	367
20	TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusionâ€“Positive Intrahepatic Cholangiocarcinoma. Cancer Discovery, 2019, 9, 1064-1079.	7.7	254
21	Functional linkage of gene fusions to cancer cell fitness assessed by pharmacological and CRISPR-Cas9 screening. Nature Communications, 2019, 10, 2198.	5.8	92
22	Genomeâ€wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy. Molecular Systems Biology, 2019, 15, e8323.	3.2	25
23	Statistical assessment and visualization of synergies for large-scale sparse drug combination datasets. BMC Bioinformatics, 2019, 20, 83.	1.2	26
24	EXTH-71. IND-ENABLING CHARACTERIZATION OF ONC206 AS THE NEXT BITOPIC DRD2 ANTAGONIST FOR NEURO-ONCOLOGY. Neuro-Oncology, 2019, 21, vi97-vi97.	0.6	1
25	A common Chk1-dependent phenotype of DNA double-strand break suppression in two distinct radioresistant cancer types. Breast Cancer Research and Treatment, 2019, 174, 605-613.	1.1	14
26	The Ewing Family of Tumors Relies on BCL-2 and BCL-XL to Escape PARP Inhibitor Toxicity. Clinical Cancer Research, 2019, 25, 1664-1675.	3.2	26
27	KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition. Clinical Cancer Research, 2019, 25, 796-807.	3.2	175
28	NOTCH1 Represses MCL-1 Levels in GSI-resistant T-ALL, Making them Susceptible to ABT-263. Clinical Cancer Research, 2019, 25, 312-324.	3.2	11
29	Redirecting T-Cells Against AML in a Multidimensional Targeting Space Using T-Cell Engaging Antibody Circuits (TEAC). Blood, 2019, 134, 2653-2653.	0.6	4
30	PARP-1 inhibition with or without ionizing radiation confers reactive oxygen species-mediated cytotoxicity preferentially to cancer cells with mutant TP53. Oncogene, 2018, 37, 2793-2805.	2.6	42
31	SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors. Nature Medicine, 2018, 24, 512-517.	15.2	155
32	Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer. Cancer Discovery, 2018, 8, 714-729.	7.7	228
33	Differential Effector Engagement by Oncogenic KRAS. Cell Reports, 2018, 22, 1889-1902.	2.9	101
34	EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma. Cancer Cell, 2018, 33, 202-216.e6.	7.7	116
35	Transcription Factor Activities Enhance Markers of Drug Sensitivity in Cancer. Cancer Research, 2018, 78, 769-780.	0.4	161
36	Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression. Clinical Cancer Research, 2018, 24, 360-369.	3.2	96

#	Article	IF	Citations
37	Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies. Cell Cycle, 2018, 17, 468-478.	1.3	34
38	Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors Through Longitudinal Analysis of Circulating Tumor DNA. JCO Precision Oncology, 2018, 2018, 1-14.	1.5	86
39	DRES-10. DRD5 IS A MODULATOR OF GLIOMA SUSCEPTIBILITY TO DRD2 ANTAGONISM BY ONC201. Neuro-Oncology, 2018, 20, vi77-vi78.	0.6	0
40	EXTH-17. SELECTIVE, NON-COMPETITIVE DRD2/3 ANTAGONISM BY IMIPRIDONE ONC206 IS EFFECTIVE IN TUMORS WITH DOPAMINE RECEPTOR DYSREGULATION. Neuro-Oncology, 2018, 20, vi88-vi88.	0.6	0
41	CellMinerCDB for Integrative Cross-Database Genomics and Pharmacogenomics Analyses of Cancer Cell Lines. IScience, 2018, 10, 247-264.	1.9	117
42	MCT2 mediates concentration-dependent inhibition of glutamine metabolism by MOG. Nature Chemical Biology, 2018, 14, 1032-1042.	3.9	22
43	AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies. Cancer Discovery, 2018, 8, 1582-1597.	7.7	310
44	Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in KRAS-Mutant Nonâ€“Small Cell Lung Cancer. Cancer Discovery, 2018, 8, 1598-1613.	7.7	71
45	BRAF and AXL oncogenes drive RIPK3 expression loss in cancer. PLoS Biology, 2018, 16, e2005756.	2.6	56
46	Targeted inhibition of histone H3K27 demethylation is effective in high-risk neuroblastoma. Science Translational Medicine, 2018, 10, .	5.8	70
47	Harnessing synthetic lethality to predict the response to cancer treatment. Nature Communications, 2018, 9, 2546.	5.8	97
48	Oligosaccharyltransferase Inhibition Overcomes Therapeutic Resistance to EGFR Tyrosine Kinase Inhibitors. Cancer Research, 2018, 78, 5094-5106.	0.4	47
49	A Novel Microtubule Inhibitor Overcomes Multidrug Resistance in Tumors. Cancer Research, 2018, 78, 5949-5957.	0.4	18
50	Target-Based Screening against eIF4A1 Reveals the Marine Natural Product Elatol as a Novel Inhibitor of Translation Initiation with In Vivo Antitumor Activity. Clinical Cancer Research, 2018, 24, 4256-4270.	3.2	41
51	TP53 mutation status: emerging biomarker for precision radiation medicine?. Oncoscience, 2018, 5, 258-259.	0.9	2
52	Radiation Resistance in KRAS-Mutated Lung Cancer Is Enabled by Stem-like Properties Mediated by an Osteopontinâ€“EGFR Pathway. Cancer Research, 2017, 77, 2018-2028.	0.4	80
53	ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells. Genes and Development, 2017, 31, 318-332.	2.7	307
54	Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212. Cell Cycle, 2017, 16, 1790-1799.	1.3	53

#	Article	IF	Citations
55	PD-L1 expression and CD8+ infiltration shows heterogeneity in juvenile recurrent respiratory papillomatosis. International Journal of Pediatric Otorhinolaryngology, 2017, 95, 133-138.	0.4	6
56	Potent Dual BET Bromodomain-Kinase Inhibitors as Value-Added Multitargeted Chemical Probes and Cancer Therapeutics. Molecular Cancer Therapeutics, 2017, 16, 1054-1067.	1.9	40
57	Detection of dysregulated protein-association networks by high-throughput proteomics predicts cancer vulnerabilities. Nature Biotechnology, 2017, 35, 983-989.	9.4	138
58	Gemcitabine and Chk1 Inhibitor AZD7762 Synergistically Suppress the Growth of Lkb1-Deficient Lung Adenocarcinoma. Cancer Research, 2017, 77, 5068-5076.	0.4	24
59	APOBEC3A and APOBEC3B Activities Render Cancer Cells Susceptible to ATR Inhibition. Cancer Research, 2017, 77, 4567-4578.	0.4	104
60	N-Arachidonoyl Dopamine Inhibits NRAS Neoplastic Transformation by Suppressing Its Plasma Membrane Translocation. Molecular Cancer Therapeutics, 2017, 16, 57-67.	1.9	13
61	Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care. Cell Reports, 2017, 21, 3298-3309.	2.9	157
62	Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors. PLoS ONE, 2017, 12, e0180541.	1.1	28
63	Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP. Oncotarget, 2017, 8, 81776-81793.	0.8	34
64	A Landscape of Pharmacogenomic Interactions in Cancer. Cell, 2016, 166, 740-754.	13.5	1,518
65	Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer. Scientific Reports, 2016, 6, 18517.	1.6	143
66	Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma. Cancer Discovery, 2016, 6, 727-739.	7.7	126
67	HER2 expression identifies dynamic functional states within circulating breast cancer cells. Nature, 2016, 537, 102-106.	13.7	335
68	Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors inALK-Rearranged Lung Cancer. Cancer Discovery, 2016, 6, 1118-1133.	7.7	919
69	Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response. Cancer Research, 2016, 76, 1313-1319.	0.4	26
70	Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination. Cancer Cell, 2016, 29, 159-172.	7.7	104
71	Single Agent and Combinatorial Efficacy of First-in-Class Small Molecule ONC201 in Acute Leukemia and Multiple Myeloma. Blood, 2016, 128, 2759-2759.	0.6	1
72	Clinical activity of ONC201 in metastatic castrate resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2016, 34, e16514-e16514.	0.8	1

#	Article	IF	Citations
73	Discovery and clinical introduction of first-in-class imipridone ONC201. Oncotarget, 2016, 7, 74380-74392.	0.8	111
74	First-in-class small molecule ONC201 in b-cell malignancies.. Journal of Clinical Oncology, 2016, 34, TPS7581-TPS7581.	0.8	0
75	Structure-activity relationships (SAR) and mechanistic analysis of clinical-stage anti-cancer small molecule ONC201 analogues.. Journal of Clinical Oncology, 2016, 34, e23161-e23161.	0.8	0
76	Potent Anti-Leukemic Effects of Small Molecule ONC212, a Member of the Imipridone Class of Anti-Cancer Compounds. Blood, 2016, 128, 5133-5133.	0.6	0
77	Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewingâ€™s Sarcoma. PLoS ONE, 2015, 10, e0140988.	1.1	72
78	Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E1288-96.	3.3	110
79	Direct pharmacological assessment of clinically acquired models as a strategy to overcome resistance to tyrosine kinase inhibitors. Molecular and Cellular Oncology, 2015, 2, e999504.	0.3	0
80	Measurement of PIP3 Levels Reveals an Unexpected Role for p110Î² in Early Adaptive Responses to p110Î±-Specific Inhibitors in Luminal Breast Cancer. Cancer Cell, 2015, 27, 97-108.	7.7	165
81	A Coding Single-Nucleotide Polymorphism in Lysine Demethylase KDM4A Associates with Increased Sensitivity to mTOR Inhibitors. Cancer Discovery, 2015, 5, 245-254.	7.7	25
82	Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors. Science, 2015, 347, 273-277.	6.0	407
83	Combined MEK and PI3K Inhibition in a Mouse Model of Pancreatic Cancer. Clinical Cancer Research, 2015, 21, 396-404.	3.2	121
84	Lysine Demethylase KDM4A Associates with Translation Machinery and Regulates Protein Synthesis. Cancer Discovery, 2015, 5, 255-263.	7.7	51
85	Adapting a Drug Screening Platform to Discover Associations of Molecular Targeted Radiosensitizers with Genomic Biomarkers. Molecular Cancer Research, 2015, 13, 713-720.	1.5	34
86	Distinct but Concerted Roles of ATR, DNA-PK, and Chk1 in Countering Replication Stress during SÂPhase. Molecular Cell, 2015, 59, 1011-1024.	4.5	266
87	Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment. PLoS ONE, 2015, 10, e0140310.	1.1	39
88	ONC201 Exhibits Mutation-Independent Efficacy with Superior Potency in Non-Hodgkin Lymphoma and Multiple Myeloma. Blood, 2015, 126, 3873-3873.	0.6	0
89	Metadata Standard and Data Exchange Specifications to Describe, Model, and Integrate Complex and Diverse High-Throughput Screening Data from the Library of Integrated Network-based Cellular Signatures (LINCS). Journal of Biomolecular Screening, 2014, 19, 803-816.	2.6	80
90	Drug/Cell-line Browser: interactive canvas visualization of cancer drug/cell-line viability assay datasets. Bioinformatics, 2014, 30, 3289-3290.	1.8	10

#	Article	IF	Citations
91	EGFR-Mediated Chromatin Condensation Protects KRAS-Mutant Cancer Cells against Ionizing Radiation. Cancer Research, 2014, 74, 2825-2834.	0.4	61
92	mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1. Cancer Discovery, 2014, 4, 42-52.	7.7	116
93	Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science, 2014, 346, 1480-1486.	6.0	635
94	Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science, 2014, 345, 216-220.	6.0	808
95	CDK4/6 and IGF1 Receptor Inhibitors Synergize to Suppress the Growth of p16INK4A-Deficient Pancreatic Cancers. Cancer Research, 2014, 74, 3947-3958.	0.4	107
96	Drugging MYCN through an Allosteric Transition in Aurora Kinase A. Cancer Cell, 2014, 26, 414-427.	7.7	231
97	Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models. Cancer Cell, 2013, 23, 121-128.	7.7	343
98	PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 21124-21129.	3.3	175
99	Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Research, 2012, 41, D955-D961.	6.5	2,363
100	Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature, 2012, 483, 570-575.	13.7	2,173
101	Preclinical evaluation of selective inhibitors of nuclear export (SINE) in basal-like breast cancer (BLBC).. Journal of Clinical Oncology, 2012, 30, 1055-1055.	0.8	7
102	BIM Expression in Treatment-NaÃ¯ve Cancers Predicts Responsiveness to Kinase Inhibitors. Cancer Discovery, 2011, 1, 352-365.	7.7	268